Hans C. Lee
0000-0001-8545-3292
Publication & Citation Trends
Publications
0 total
Linvoseltamab in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM) in the LINKER-MM1 Study: Longer Follow-up and Subgroup Analyses
Cited by 1
Semantic Scholar
Linvoseltamab in Patients With Relapsed/Refractory Multiple Myeloma in the LINKER-MM1 Study: Longer Follow-Up and Subgroup Analyses.
Cited by 3
Semantic Scholar
Real-World Healthcare Resource Utilization and Costs Among Triple-Class–Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM) Patients With and Without Extramedullary Disease in the United States
Cited by 0
Semantic Scholar
Patient-Reported Quality of Life with Linvoseltamab in Triple-Class Exposed Patients with Relapsed/Refractory Multiple Myeloma: 2-year Results from the LINKER-MM1 Phase 1/2 Clinical Trial
Cited by 1
Semantic Scholar
Comparative Efficacy of linvoseltamab versus Idecabtagene Vicleucel and Ciltacabtagene Autoleucel in Triple-Class Exposed Relapsed/Refractory Multiple Myeloma: A Matching-Adjusted Indirect Comparison
Cited by 2
Semantic Scholar
Indirect Comparison of Linvoseltamab Versus Teclistamab for the Treatment of Triple-Class Exposed Relapsed/Refractory Multiple Myeloma.
Cited by 4
Semantic Scholar
P-402 Indirect Comparison of Linvoseltamab Versus Teclistamab for Triple-Class Exposed (TCE) Relapsed/Refractory Multiple Myeloma (RRMM): An Updated Analysis Based on 14-Month Follow-Up Data
Cited by 2
Semantic Scholar
Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody.
Cited by 7
Semantic Scholar
Research Topics
Multiple Myeloma Research and Treatments
(353)
Protein Degradation and Inhibitors
(121)
Chronic Lymphocytic Leukemia Research
(71)
Chronic Myeloid Leukemia Treatments
(56)
Peptidase Inhibition and Analysis
(55)
Affiliations
Scripps Research Institute
National Institutes of Health
Northwell Health
Salk Institute for Biological Studies
West Virginia Department of Education